Kiralis Technologies

Enantiomer Separation

Health Tech & Life Sciences
Non Active, Mar 2022 ceased to operate
Seed Founded 2018
Total raised
$3.0M
Last: Seed 2018-09
Stage
Seed
Founded
2018
Headcount
3
HQ
Sector
Health Tech & Life Sciences

About

Kiralis Technologies is developing a commercial-level application for separating chiral molecules with only minor modifications for each class of racemic solution in order to achieve a high-purity repeatable product. The technology targets racemic solutions that are not separated in the pharmaceutical, pesticide, herbicide, flavor, or fragrance markets. This process was enabled by the discovery of chiral-induced spin selectivity by Professor Naaman from the Weizmann Institute and Professor Paltiel from the Hebrew University, who discovered a phenomenon they defined as chiral-induced spin selectivity (CISS). In a May 2018 article in Science, they demonstrated how the CISS effect could be exploited to separate enantiomers in a racemic mixture through the application of a magnetic field.

Funding history · 1 round · $3.0M total

2018-09
Seed $3.0M

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsIndustrial ManufacturingAgriculture & FoodProcessed Foods
Business model
B2B

Highlights

1 PatentsVerified

Tags

healthcare-providersbiotechnologypharmaceuticalsagtechchemicalsagriculture